Gilead Sciences: U.S. Military Veteran Battles Lymphoma With Car T-Cell Therapy: Marcus' Story
Marcus, a 36-year-old military veteran, was diagnosed with diffuse large B-cell lymphoma after noticing unusual growths. Although he achieved remission following six rounds of chemotherapy, the cancer returned aggressively, affecting his trigeminal nerve.
He was then referred to the University of Maryland Greenebaum Comprehensive Cancer Center, where he received CAR T-cell therapy. The initial PET CT scan revealed a dramatic response to the treatment. Grateful for the opportunity to spend precious time with his son, Marcus emphasized the importance of life and family.
- Successful initial response to CAR T-cell therapy indicated by PET CT scan.
- Access to advanced treatment options at a leading cancer center.
- Cancer recurrence after initial chemotherapy treatment.
- Aggressive nature of the lymphoma presenting significant health challenges.
NORTHAMPTON, MA / ACCESSWIRE / December 8, 2022 / Marcus arrived home to Mississippi from his military assignment overseas, excited to see his 20-month-old son, when he realized something was wrong.
"I started noticing that I had a little growth right here on my neck. About two weeks later, I had a growth in my left groin area, the size of a softball," recalls Marcus. "I was like, this isn't right. I'm 36 years old, and I had never been sick in my life."
It was cancer - a type of blood cancer known as diffuse large B-cell lymphoma.
After receiving his diagnosis, Marcus was driven to beat it. "There's no way I'm going to let this disease get the best of me and not be here to raise my son and see him grow up."
But his journey wasn't easy. After six rounds of chemotherapy, Marcus' cancer went into remission, but it was short-lived. Marcus noticed a numbing sensation on the side of his face. His lymphoma had relapsed and returned as a tumor on his trigeminal nerve.
"The second time it hit me a lot harder. I wasn't expecting it to come back," says Marcus.
His doctor at Walter Reed National Military Medical Center referred him to an hematologist-oncologist at University of Maryland Greenebaum Comprehensive Cancer Center, where he received CAR T-cell therapy.
"He had a very aggressive presentation of lymphoma. Being able to offer CAR T-cell therapy was a welcome opportunity for him," says Dr. Aaron Rapoport, the cancer center's Director of Transplant and Cellular Therapy.
The first PET CT scan showed a dramatic response to the treatment.
"I'm forever grateful," says Marcus. "I spend every moment that I can with my son because life is precious. Tomorrow is not promised. I have one son. He's going to get all of me."
View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.
Contact Info:
Spokesperson: Gilead Sciences
Website: http://www.gilead.com/
Email: info@3blmedia.com
SOURCE: Gilead Sciences
View source version on accesswire.com:
https://www.accesswire.com/730906/Gilead-Sciences-US-Military-Veteran-Battles-Lymphoma-With-Car-T-Cell-Therapy-Marcus-Story
FAQ
What type of cancer was Marcus diagnosed with?
What treatment did Marcus receive after his cancer relapsed?
What was the outcome of the CAR T-cell therapy for Marcus?
How many rounds of chemotherapy did Marcus undergo before CAR T-cell therapy?
Why is Marcus determined to fight his illness?
